三個皮匠報告
政策庫
new
付費
搜索

圖25.賽默制藥對內完成的受托研發項目數量-行業數據

圖25.賽默制藥對內完成的受托研發項目數量
圖25.賽默制藥對內完成的受托研發項目數量
項目訂單情況，截止到 2022 年底，賽默制藥已承接了超過 360 個項目，與超過 100 家企業深度合作。2022 年賽默制藥的 CDMO 服務實現營收 6009.31 萬元，其中承接外部客戶 CDMO 訂單實現營收 2080.22 萬元，同比增長 121.27%。
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?3KB 圖片尺寸：1222*969
同報告圖片
 / 35
圖25.賽默制藥對內完成的受托研發項目數量_第1頁
5qC55o2u5Zu+54mH5Lit55qE5p+x54q25Zu+5pWw5o2u77yM5Lul5LiL5piv6LWb6buY5Yi26I2v5a+55YaF5a6M5oiQ55qE5Y+X5omY56CU5Y+R6aG555uu5pWw6YeP55qE6KGo5qC877yaCgp8IOW5tOS7vSB8IOWPl+aJmOeglOWPkemhueebruaVsOmHjyB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwKfCAyMDIxIHwgNjAgICAgICAgICAgICAgfAp8IDIwMjIgfCAxNTAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7jlhazlkYrjgIFXaW5k44CB5a6J5L+h6K+B5Yi456CU56m25Lit5b+D
圖25.賽默制藥對內完成的受托研發項目數量_第2頁
圖25.賽默制藥對內完成的受托研發項目數量_第3頁
fCDlubTku70gfCDlm73lhoXkuK3miJDoja/ooYzkuJrluILlnLrop4TmqKHvvIjkur/lhYPvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IDIwMTUgfCA2MDAwICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMTkgfCA4MDAwICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjRFfCAxMTAwMCAgICAgICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaRXVyb21vbml0b3LjgIHlhazlj7jlhazlkYrjgIHlronkv6Hor4HliLjnoJTnqbbkuK3lv4M=
圖25.賽默制藥對內完成的受托研發項目數量_第4頁
圖25.賽默制藥對內完成的受托研發項目數量_第5頁
圖25.賽默制藥對內完成的受托研發項目數量_第6頁
圖25.賽默制藥對內完成的受托研發項目數量_第7頁
圖25.賽默制藥對內完成的受托研發項目數量_第8頁
fCDliIbnsbsgICAgICAgICAgfCAyMDE45bm0IHwgMjAxOeW5tCB8IDIwMjDlubQgfAp8LS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLXwtLS0tLS0tLS18LS0tLS0tLS0tfAp8IOWItuiNr+S8geS4miAgICAgIHwgNjAgICAgICB8IDgwICAgICAgfCAxMDAgICAgIHwKfCDljLvoja/noJTlj5HmipXotYTkvIHkuJogfCAxMCAgICAgIHwgMjAgICAgICB8IDMwICAgICAgfAp8IOWFtuS7luS8geS4miAgICAgIHwgNSAgICAgICB8IDUgICAgICAgfCAxMCAgICAgIHw=
圖25.賽默制藥對內完成的受托研發項目數量_第9頁
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
圖25.賽默制藥對內完成的受托研發項目數量_第10頁
圖25.賽默制藥對內完成的受托研發項目數量_第11頁
圖25.賽默制藥對內完成的受托研發項目數量_第12頁
圖25.賽默制藥對內完成的受托研發項目數量_第13頁
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
圖25.賽默制藥對內完成的受托研發項目數量_第14頁
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
圖25.賽默制藥對內完成的受托研發項目數量_第15頁
圖25.賽默制藥對內完成的受托研發項目數量_第16頁
圖25.賽默制藥對內完成的受托研發項目數量_第17頁
圖25.賽默制藥對內完成的受托研發項目數量_第18頁
圖25.賽默制藥對內完成的受托研發項目數量_第19頁
5qC55o2u5Zu+54mH5Lit55qE5p+x54q25Zu+5pWw5o2u77yM5Lul5LiL5piv6LWb6buY5Yi26I2v5a+55YaF5a6M5oiQ55qE5Y+X5omY56CU5Y+R6aG555uu5pWw6YeP55qE6KGo5qC877yaCgp8IOW5tOS7vSB8IOWPl+aJmOeglOWPkemhueebruaVsOmHjyB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwKfCAyMDIxIHwgNjAgICAgICAgICAgICAgfAp8IDIwMjIgfCAxNTAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7jlhazlkYrjgIFXaW5k44CB5a6J5L+h6K+B5Yi456CU56m25Lit5b+D
圖25.賽默制藥對內完成的受托研發項目數量_第20頁
圖25.賽默制藥對內完成的受托研發項目數量_第21頁
圖25.賽默制藥對內完成的受托研發項目數量_第22頁
圖25.賽默制藥對內完成的受托研發項目數量_第23頁
圖25.賽默制藥對內完成的受托研發項目數量_第24頁
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
圖25.賽默制藥對內完成的受托研發項目數量_第25頁
圖25.賽默制藥對內完成的受托研發項目數量_第26頁
圖25.賽默制藥對內完成的受托研發項目數量_第27頁
圖25.賽默制藥對內完成的受托研發項目數量_第28頁
圖25.賽默制藥對內完成的受托研發項目數量_第29頁
圖25.賽默制藥對內完成的受托研發項目數量_第30頁
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
圖25.賽默制藥對內完成的受托研發項目數量_第31頁
圖25.賽默制藥對內完成的受托研發項目數量_第32頁
圖25.賽默制藥對內完成的受托研發項目數量_第33頁
5aW955qE77yM5Lul5LiL5piv5oKo5Zu+54mH5Lit55qE5pWw5o2u5Lul5Y+K6LWE5paZ5p2l5rqQ77yaCgp8IOaguOW/g+aKgOacr+aIkOWRmCB8IOWtpuWOhuiDjOaZryB8IOiBjOWKoSB8IOi1hOi0qOWPiue7j+mqjCB8CnwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tfC0tLS0tLXwtLS0tLS0tLS0tLS18Cnwg5qW86YeR6IqzICAgICAgICB8IOehleWjq+eglOeptueUnyB8IOiRo+S6i+mVv+OAgeaAu+e7j+eQhiB8IOaLpeaciTMw5bm06I2v54mp56CU56m255u45YWz55qE5bel5L2c57uP6aqM77yM5pu+5Zyo5rW35Y2X5pmu5Yip5ouF5Lu76I2v54mp56CU56m25omA5omA6ZW/562J6IGM5Yqh44CC54af5oKJ6I2v5ZOB56CU5Y+R5rWB56iL44CB5rOV5b6L5rOV6KeE5ZKM5ZCE57G75oyH5a+85Y6f5YiZ77yM5ZCM5pe25YW35aSH5Zu95YaF5aSW6I2v54mp5rOo5YaM55Sz5oql57uP6aqM44CC55uu5YmN5bey5bim6aKG55m+6K+a5Yy76I2v5Y+K5a2Q5YWs5Y+45oiQ5Yqf56CU5Y+RMjDlpJrkuKroja/nianlk4Hnp43vvIzkuJrliqHpoobln5/opobnm5bku7/liLboja/lj4rliJvmlrDoja/nmoTnoJTlj5Hlj4rms6jlhoznlLPmiqXjgILlt7Llj5Hooajorrrmloflj4rlh7rniYjniakxM+evh++8jOebruWJjeS4uua1meaxn+Wkp+WtpuiNr+WtpuS4k+S4muWtpuS9jeeglOeptueUn+agoeWkluWvvOW4iCB8Cnwg6LS+6aOeICAgICAgICAgfCDnoZXlo6vnoJTnqbbnlJ/vvIzkuK3lm73ljLvnp5HlpKflraboja/lrablo6sgfCDlia/mgLvnu4/nkIYgfCDmm77lnKjmtZnmsZ/nnIHpo5/lk4Hoja/lk4Hmo4DpqoznoJTnqbbpmaLlkozmtZnmsZ/nnIHoja/lk4HljJblpoblk4HlrqHor4TkuK3lv4Plt6XkvZwxNuW5tO+8jOWIhuWIq+S6jjIwMDnlubTlkowyMDE15bm05Lik5qyh5Zyo5Zu95a626I2v55uR5bGA6I2v5ZOB5a6h6K+E5Lit5b+D5oyC6IGM5LuO5LqL5paw6I2v5rOo5YaM5oqA5pyv5a6h6K+E5bel5L2c44CC5pu+5Lu75Zu95a626I2v55uR5bGA6I2v5ZOB5a6h6K+E5Lit5b+D6I2v5ZOB5Li75a6h5ZGY44CB5rWZ5rGf55yBR01Q5qOA5p+l57uE6ZW/5ZKM6I2v5ZOB5rOo5YaM5qC45p+l57uE6ZW/44CC5Y+C5LiO5rWZ5rGf55yB56eR5oqA5Y6F56eR5oqA6aG555uu6K++6aKY5aSa5Liq77yM5Zyo5Zu95YaF5aSW5qC45b+D5pyf5YiK5Y+R6KGo5paH56ugMjDkvZnnr4cgfAp8IOWImOaMr+WNjiAgICAgICB8IOa1meaxn+Wkp+WtpuiNr+WtpuWNmuWjqyB8IOadreW3nueZvuadj+eUn+eJqeWIhuaekOmDqOaKgOacr+aAu+ebkSB8IOaLpeaciTEw5aSa5bm056CU5Y+R57uP6aqM77yM5YWI5ZCO5Zyo5aSa5a625Zu95YaF55+l5ZCN5LyB5Lia5Y+C5LiO5paw6I2v56CU56m25byA5Y+R44CB6I2v5Luj5Yqo5Yqb5a2m5ZKM5Lu/5Yi26I2vQkXor4Tku7flt6XkvZzvvIznhp/mgonlm73lhoXlpJbms5Xop4TlkoznoJTlj5HmtYHnqIvvvIzlhbfmnInkuLDlr4znmoToja/lk4HnoJTlj5Hlkozpobnnm67nrqHnkIbnu4/pqozvvIzlkozpobnnm67nrqHnkIbnu4/pqozvvIzkvZzkuLrlj5HmmI7kurrkuYvkuIDojrflvpc06aG55LiT5Yip77yM55Sz6K+35LiT5YipMemhuSB8Cnwg5p2O6Imz6Iq5ICAgICAgIHwg56GV5aOr56CU56m255SfIHwg5rOo5YaM6YOo6aG555uu566h55CG5oC755uRIHwg5oul5pyJ5LiJ5Y2B5aSa5bm055qE5paw6I2v56CU5Y+R57uP6aqM77yM5Li75oyB6LSf6LSj55qE6aG555uu6I635b6X5paw6I2v6K+B5Lmm5oiW6ICF55Sf5Lqn5om55Lu2MzDlpJrkuKrvvIzkuLvmjIHotJ/otKPlm73lrrbotYTliqnpobnnm64x5Liq77yM5biC6LWE6YeR6LWE5Yqp6aG555uuM+S4qu+8jOS7peS4gOS9nOWPkeihqOiuuuaWhzfnr4fvvIznlLPor7fkuJPliKk16aG5IHwKfCDmsarljavlhpsgICAgICAgfCDnoZXlo6vnoJTnqbbnlJ8gfCDmtrLkvZPliLbliYLkuozpg6jmgLvnu4/nkIYgfCDmi6XmnIkyMOW5tOWMu+iNr+eglOWPkeWPiueuoeeQhue7j+mqjO+8jOabvui0n+i0o+WkmumhueWOn+aWmeiNr+OAgeWbuuS9k+WItuWJguWPiuazqOWwhOWJgumhueebrueUs+aKpe+8jOW5tuiOt+W+l+eUn+S6p+aJueaWh+S4iuW4giB8CgrotYTmlpnmnaXmupDvvJrmi5vogqHor7TmmI7kuabjgIHlronkv6Hor4HliLjnoJTnqbbkuK3lv4M=
圖25.賽默制藥對內完成的受托研發項目數量_第34頁
圖25.賽默制藥對內完成的受托研發項目數量_第35頁
圖25.賽默制藥對內完成的受托研發項目數量_第36頁
所屬報告： 百誠醫藥-公司研究報告-藥學研究+臨床試驗+定制研發生產綜合藥物研發及生產的一體化大平臺逐步隱現-230813（25頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站